BioVie Earnings Call Transcripts
Fiscal Year 2026
-
Two major clinical readouts are expected soon for Parkinson's and Long COVID, with both trials showing promising safety and early efficacy signals. Bezisterim, the lead asset, targets inflammation and insulin resistance, offering a differentiated approach with significant market potential.
-
The event highlighted the central role of metabolic dysregulation and inflammation in neurodegenerative diseases, with bezisterim positioned as a novel anti-inflammatory agent targeting both motor and non-motor symptoms in Parkinson's. Key biomarkers include DNA methylation and biological age, with trial results expected by end of Q2 or early Q3.
-
The presentation highlighted imminent clinical data readouts for bezisterim in Parkinson's and long COVID, both representing multi-billion dollar U.S. market opportunities. The company is advancing a spin-off for its liver disease asset and is considered undervalued with strong insider ownership.
-
Bezisterim is advancing in phase II trials for Parkinson's and long COVID, with key data readouts expected in Q2 and late summer 2024. BIV201 for ascites is preparing for phase III after strong phase II results. Strategic focus is on Parkinson's, with long COVID as a potential priority if results and FDA guidance are favorable.
Fiscal Year 2025
-
The meeting established a quorum, elected six directors for a one-year term, ratified EisnerAmper, LLP as auditor for 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan. All proposals passed with strong majority support.
-
Multiple clinical trials are progressing, with key data readouts for Parkinson's, Long COVID, and ascites expected by mid-2026. Lead drug bezisterim targets TNF-alpha and shows promise in neurodegenerative and inflammatory conditions, while financial runway extends through 2026.
-
A quorum was established with nearly all shares represented. Shareholders approved both the reverse stock split proposal and the adjournment authority, with over 79% and 81% support, respectively.
-
The event detailed the rationale and design for a phase II trial of Bezisterim, an oral anti-inflammatory targeting NF-kappa B, in early Parkinson's disease. Bezisterim aims to address both motor and non-motor symptoms by reducing neuroinflammation and improving insulin signaling, with a unique trial design enabling home-based participation and robust biomarker analysis.
Fiscal Year 2024
-
The meeting confirmed a quorum, elected six directors, and approved all major proposals, including auditor ratification, executive compensation, and an increase in shares for the equity incentive plan. Over 60% of shares were represented, with strong support for each item.